INS (insulin; HGNC:3619, NCBI Gene 3630) is the gene on chromosome 11p15.5 encoding preproinsulin — the 110-amino-acid precursor whose signal peptide is cleaved to proinsulin, then processed to the two-chain, 51-amino-acid insulin peptide within the beta cell's secretory granules. It is expressed almost exclusively in pancreatic islet beta cells, glucose-regulated through the INS promoter's glucose-response elements. The insulin hormone page is the canonical physiology reference; this gene page covers the locus, its regulation, and the monogenic-diabetes genetics.
Approved Symbol
INS (HGNC:3619)
Chromosomal Locus
11p15.5 (with IGF2 in the imprinted H19/IGF2 region neighborhood)
Encoded Product
Preproinsulin (110 aa) → proinsulin → insulin (A chain 21 + B chain 30 aa + C-peptide)
Primary Pathway
Glucose → beta-cell K-ATP closure → calcium → INS transcription and secretion
Clinical / Therapeutic Role
Type 1 diabetes's absent hormone; MODY and neonatal-diabetes mutations; recombinant insulin therapy
Gene Structure & Expression
Genomic organization: Three exons — exon 1 (5' untranslated), exon 2 (signal peptide, B chain, C-peptide start), exon 3 (C-peptide end, A chain) — with promoter elements (A3/E1, glucose-responsive; PDX1, NEUROD1, MAFA binding sites) that define beta-cell identity.
Expression: Beta-cell specific; the 11p15.5 VNTR (variable number tandem repeat) upstream polymorphism modestly influences expression and type-1-diabetes susceptibility — the locus's classic IDDM2 association.
Molecular Function & Pathways
Biosynthesis and processing: Glucose metabolism raises ATP, closes K-ATP channels, and depolarises the beta cell (see ion channels); calcium influx both triggers secretion of stored insulin and drives INS transcription; prohormone convertases (PC1/3, PC2) and carboxypeptidase E process proinsulin to insulin plus C-peptide — equimolar co-secretion as the clinical readout.
ER-folding quality control: Proinsulin's disulfide-bonded folding in the ER — misfolding variants (Akita-type) triggering ER stress and beta-cell death, the permanent-neonatal-diabetes mechanism; wild-type demand on ER capacity in insulin resistance contributing to beta-cell exhaustion.
Clinical & Therapeutic Significance
Diabetes genetics: Type 1 diabetes — autoimmune beta-cell destruction leaves the intact gene unexpressed (exogenous insulin's replacement role); heterozygous INS mutations cause MODY10 and permanent neonatal diabetes; the INS promoter-VNTR's IDDM2 risk modulation.
Therapeutics: Recombinant insulin (the first recombinant-DNA drug, 1982) and its analogues (lispro, glargine, degludec) — the gene's product as medicine at global scale; proinsulin/C-peptide assays distinguishing endogenous from injected insulin.